Can Quality-Adjusted Life Year Avoidance Help in Oncology Drug Reimbursement Decisions?
نویسندگان
چکیده
منابع مشابه
Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.
BACKGROUND In many countries, the incremental cost-effectiveness ratio (ICER) is used to assess whether an intervention is worth its costs. At the same time, policy makers often feel uncomfortable with refusing reimbursement of any intervention purely on the basis of the fact that the ICER exceeds a specific threshold value. Reluctance to define a single threshold value for the ICER seems to ha...
متن کاملAdding Extrinsic Goals to the Quality-Adjusted Life Year Model
M for evaluating health quality are central to medical decision analyses. The most important such method is the quality-adjusted life year (QALY), in which a patient’s length of life is given weight proportional to his/her quality of health. QALYs have become ubiquitous in medical cost-effectiveness as a measure of preference for health outcomes. However, numerous studies have demonstrated that...
متن کامل“Budget Impact Analyses”: a practical policy making tool for drug reimbursement decisions
Increasing accessibility and affordability of healthcare services has been considered as an important policy objective since the beginning of 1980s in Iran. However, current 60- 70% health care out-of-pocket payments create a barrier to an equal access to quality health services, especially in terms of new medicines which affects equity issues and "health" in Iran. Currently, health insurance o...
متن کاملWillingness to pay per quality-adjusted life year for life-saving treatments in Thailand
OBJECTIVE To estimate the willingness to pay (WTP) per quality-adjusted life year (QALY) value for life-saving treatments and to determine factors affecting the WTP per QALY value. DESIGN A cross-sectional survey with multistage sampling and face-to-face interviews. SETTING General population in the southern part of Thailand. PARTICIPANTS A total of 600 individuals were included in the st...
متن کاملCurrent issues in oncology reimbursement.
The reimbursement policies of Medicare, Medicaid, and private insurers can have a major impact on the ability of oncologists to deliver care to their patients. This article explores current issues of particular interest to oncologists, including coverage of off-label drug uses, reimbursement for drugs used in clinical trials and for costs of care for patients in trials, the effect of DRGs on th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Oncology Practice
سال: 2008
ISSN: 1554-7477,1935-469X
DOI: 10.1200/jop.0711501